

Alongside great promise is known human and algorithmic bias in Healthcare applications

- AI supporting **complex** cognitive tasks currently performed by medical specialists
 - Assessment, diagnosis and treatment
- AI **bias in other domains** are well described, which reinforce existing social inequity
 - Facial recognition for non-binary individuals
 - Automated parole decisions for people of color (Buolamwini & Gebru, 2018)
- Selected **two areas** of healthcare applications – illustrative examples how bias can manifest in AI
 1. Treatment – prostate cancer
 2. Diagnosis – mental health

To develop *trustworthy* AI we must attend to Equity

Prostate cancer treatment selection is ambiguous and stressful ... and wrought with bias

- Persistent **racial disparities** in prevalence and mortality – African American Men (AAM) show 3.0-fold higher mortality risk (Di Pietro, Chornokur, Kumar, Davis, & Park, 2016)
- Multi-faceted **drivers** of disparities, differences in treatment (Division of Cancer Control and Population Sciences (DCCPS), 2019)(Hoffman et al., 2001)
 - AAM receive less decisive treatment (e.g., radiation therapy, radical prostatectomy, or combination therapy) than White men (52.0% vs. 64.8%, $P < 0.001$) (Mahal et al., 2014)(Moses, Orom, Brasel, Gaddy, & Underwood, 2016)
- Treatment selection **strongly associated** with physician recommendations (Aning, Wassersug, & Goldenberg, 2012)(Ramsay et al., 2011)(Saigal, Lambrechts, Seenu Srinivasan, & Dahan, 2017)(van Tol-Geerdink et al., 2013)
- Pertinent bias in **clinical encounters**
 - Physicians perceive that African American patients are less effective communicators than White patients (Street, Gordon, & Haidet, 2007)
 - Physicians are more contentious and more verbally dominant with African American patients (Johnson, Saha, Arbelaez, Beach, & Cooper, 2004)

Underrepresentation in research presents a persistent risk of bias

- AAM **underrepresented** in cancer research, from the bench, to the bedside, to communities (Ahaghotu, Tyler, & Sartor, 2016)(Byrne, Tannenbaum, Glück, Hurley, & Antoni, 2013)
- Lack of representation is enduring public health **concern** – presents potential barriers to racially equitable development of strategies for prevention and treatment (Reifenstein & Asare, 2018)
 - Machine learning being used to identify gene expression to predict prostate cancer outcomes. Bolsters promise of personalized medicine by determining “optimal” treatment (Goldenberg, Nir, & Salcudean, 2019)
- Socio-technical barriers (e.g., trust) present **barriers** to research and use of IT-enabled tools

To develop *trustworthy* AI we must attend to Equity

Mental health assessment and access must attend to bias, especially pertaining to gender

- Gender **inequities** in mental health assessment, which include conceiving gender as binary (Spiel, Keyes, & Barlas, 2019)
- “Disorder” is **socially constructed** and mental illness highly **stigmatized**
- Patient **consent** required for storing and diagnostic profiling
- Practitioners should understand **risk** of bias and use of AI as **adjunctive** method to inform diagnosis, and treatment selection

Must identify and target appropriate diagnostics & treatment selection

- AI can **address** inequity in outcomes, but can also **exacerbate** them
- Current understanding of bias can **inform taxonomy** of illness types which address social determinants of health, inequities to access, and acuteness and chronicity of various health conditions
- Taxonomy can aid in **focus** of future research
 - Prostate cancer – **toolkits** and **workflows** which help prompt physicians to understand source of bias in treatment selection and gaps in current understanding of prognosis considering patient preferences and values
 - Mental health – careful **operationalizing** of gender, mental health assessment, and patient consent

Fulfilling AI potential must require identifying bias & mitigating its deleterious effects – doing so will translate to equitable gains